Skip Ribbon Commands
Skip to main content

Title

Acceptability of drug detection monitoring among participants in an open-label pre-exposure prophylaxis study.

Authors

KA Koester, A Liu, C Eden, et al

Network Affiliation

Other

Organization

 

Journal Name

AIDS Care

Publication Date

5/22/2015

PubMed Search

http://www.ncbi.nlm.nih.gov/pubmed/26001026

Link to full-text

 

PMID

26001026

Abstract

​In the world of HIV pre-exposure prophylaxis (PrEP) research, there is emerging interest in providing study participants with pharmacokinetic results from drug level testing to guide adherence counseling. The iPrEx randomized control trial was the first study to produce meaningful results of PrEP in humans. In the iPrEx open-label extension (OLE) study, blood plasma samples collected in the first 12 weeks of study participation were tested for the presence of tenofovir/emtricitabine - the drugs which compromise PrEP. Study clinicians shared results (detectable/undetectable) with participants at their 24-week visit. We evaluated the acceptability of receiving these results among a subset of iPrEx OLE participants. We conducted in-depth interviews (n = 59) with participants (those with and those without drug detected) enrolled in Boston, Chicago, and San Francisco to assess their experiences with receiving drug detection feedback. Incorporating drug detection results into the clinical study visit was well received and no negative reactions were expressed. For about half of participants, receiving their drug detection lab result was useful while for others it was not important. In a few cases, no drug detected results led to increased efforts to take PrEP consistently and in most cases enhanced open discussion of missed doses. Participants reported a desire for greater specificity, particularly quantitative drug levels needed for protection. We recommend exploring strategies to increase the salience of drug level results, including using feedback to target adherence counseling, and reducing the time between specimen collection, testing, and receipt of results. Future studies should evaluate the feasibility and impact of providing more specific quantitative drug levels using biomarkers of longer term PrEP exposure, i.e., hair/dried blood spots.

Keywords

 

Topic

Adherence; Behavior

Attachments

Created at 6/5/2015 10:23 AM by Davis, Gregory P
Last modified at 6/5/2015 10:23 AM by Davis, Gregory P